Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Its products include metered-dose spray, liposomal gel encapsulates, and intranasal spray. The company was founded by Anthony P. Mack and Jeffrey A. Gudin in 2016 and and is headquartered in Berwyn, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments. “We successfully completed our initial public offering (IPO) of 1,800,000 shares of our common stock in mid-February and immediately began our IND enabling studies for Epoladerm™ and Envelta™, so that we can meet with the FDA and initiate first-in-human trials. Additionally, we recently r

Virpax Pharmaceuticals Reports 2021 First Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #licensing--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced that the Company has engaged Torreya Capital, LLC (Torreya) to serve as the exclusive financial advisor for the Company's partnering and licensing efforts in strategic global markets. Torreya is a global investment bank that has facilitated more than $100 billion worth of transactions in the life sciences industry since its inception in 2007. “We are excited to be working with

Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has announced preclinical results of MMS019, its anti-viral product candidate for respiratory viruses. MMS019 is a high-density molecular masking spray the Company is developing as an anti-viral barrier.

Virpax's Anti-Viral Candidate Reduced Nasal, Brain Viral Load In Animal Study

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical product candidates for pain management, today announced the results of an animal study model for MMS019, its anti-viral product candidate for respiratory viruses. MMS019 is high-density molecular masking spray the Company is developing as an anti-viral barrier. The Company intends for this formulation to be delivered using a preassembled devi

Virpax's MMS019 Reduced Nasal and Brain Viral Load in Animal Study

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has announced data from a sciatic nerve preclinical study designed to evaluate Probudur, Virpax's liposomal bupivacaine product candidate. This study's objective was to assess neurotoxicity resulting from a long residence time of a local anesthetic in proximity to the sciatic nerve in rabbits.

Virpax's Liposomal Bupivacaine Candidate Associated With No Neurotoxicity In Animal Studies

BERWYN, PA / ACCESSWIRE / April 5, 2021 / Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical product candidates for pain management, today announced the results of a sciatic nerve preclinical study in rabbits designed to evaluate nerve damage from locally injected Probudur™, Virpax's liposomal bupivacaine product candidate. "Local anesthetics can be neurotoxic, particularly in doses and concentrations larger than those used clinically.

Virpax Announces Results of Probudur(TM) in Animal Study

BERWYN, PA / ACCESSWIRE / March 22, 2021 / Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that preclinical studies of Probudur™, a proprietary patented injectable, long-acting "local anesthetic" Liposomal (Hydro) Gel Technology for postoperative pain management, have been initiated under an agreement with Charles River Laboratories. Under the terms of the agreement, Charles River Laboratories will perform seven preclinical animal studies including method, dosage, and toxicity as part of the required U.S. Food and Drug Administration ("FDA") enabling trials for an Investigational New Drug Application ("IND") for Probudur™.

Virpax to Initiate Investigational New Drug (IND) Enabling Studies for Probudur(TM) for Postoperative Pain

News for Virpax Pharmaceuticals Stock (VRPX)